APLLTD — Alembic Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapFalling Star

Annual income statement for Alembic Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,058	53,931	53,058	56,526	62,286
Cost of Revenue
Gross Profit	31,892	37,531	34,618	34,779	40,546
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	35,921	40,963	47,183	52,148	55,679
Operating Profit	10,136	12,968	5,875	4,378	6,607
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,998	13,681	6,201	3,546	6,318
Provision for Income Taxes
Net Income After Taxes	8,006	11,148	5,157	3,420	6,158
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	8,288	11,465	5,209	3,420	6,158
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,288	11,465	5,209	3,420	6,158
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	48.1	59.1	26.5	17.6	31.2
Dividends per Share
Special Dividends per Share